首页>
外国专利>
USE OF AN ANTI-CD2 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
USE OF AN ANTI-CD2 ANTIBODY DRUG CONJUGATE (ADC) IN ALLOGENEIC CELL THERAPY
展开▼
机译:在同种异体细胞疗法中使用抗CD2抗体药物缀合物(ADC)
展开▼
页面导航
摘要
著录项
相似文献
摘要
The invention provides methods of depleting CD2+ cells in human patients undergoing chimeric antigen receptor (CAR) immunotherapy in order to promote acceptance of CAR expressing immune cells. Anti-CD2 antibody drug conjugates (ADCs) are administered as a conditioning regimen to a human patient receiving autologous or allogeneic CAR expressing immune cells such that the CAR expressing immune cells are accepted by the human patient. Compositions and methods of the invention can be used in combination with CAR therapy to treat a variety of pathologies, including autoimmune diseases and cancer.
展开▼